VistaGen Therapeutics Inc

NASDAQ:VTGN  
2.80
-0.04 (-1.58%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)524.15M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.31 Million
Adjusted EPS-$0.05
See more estimates
10-Day MA$2.68
50-Day MA$2.39
200-Day MA$1.63
See more pivots

VistaGen Therapeutics Inc Stock, NASDAQ:VTGN

343 Allerton Avenue, South San Francisco, California 94080
United States of America
Phone: +1.650.577.3600
Number of Employees: 9

Description

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company's portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for Phase III clinical trial for social anxiety disorder (SAD), PH10, a neuroactive nasal spray that the company is planning for Phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101 which the Company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.